Aptabio Obtains Patent for Eye Disease Treatment
[Asia Economy Reporter Minwoo Lee] Aptabio announced on the 9th that it has jointly obtained a patent for an 'ophthalmic disease treatment composition' with Samjin Pharmaceutical.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
The patent relates to a pharmaceutical composition for treating ophthalmic diseases containing pyrazole-based compounds and biodegradable polymers. The composition allows the drug to reach the posterior segment of the eye while simultaneously extending the duration of the drug's action within the eye. Aptabio plans to utilize this patent in the development of treatments for ophthalmic diseases.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
